HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mollnes, T. E. Articles by Oppermann, M. Search for Related Content PubMed PubMed Citation Articles by Mollnes, T. E. Articles by Oppermann, M.

The Annals of Thoracic Surgery, Vol 52, 92-97, Copyright © 1991 by The Society of Thoracic Surgeons

ARTICLES

Formation of C5a during cardiopulmonary bypass: inhibition by precoating with heparin

TE Mollnes, V Videm, O Gotze, M Harboe and M Oppermann
Institute of Immunology and Rheumatology, National Hospital, Oslo, Norway.

A novel enzyme immunoassay based on direct detection of C5a by a monoclonal antibody (C17/5) specific for a neoepitope exposed in C5a/C5adesArg was used to measure in vivo and in vitro C5a formation during cardiopulmonary bypass. In vivo, we observed a significant threefold to fourfold increase in patient plasma C5a/C5adesArg levels from baseline values (5.6; 1.6 to 12.9 ng/mL) (median and range) up to 42 hours postoperatively (17.5; 6.5 to 46.0 ng/mL) when two different uncoated cardiopulmonary bypass circuits were used. Coating of the extracorporeal circuit with end-point-attached heparin completely abolished C5a formation in vitro during circulation of blood through the circuit for 120 minutes. The C5a concentration (median and range) was 3.2 (2.6 to 15.9) ng/mL at the start and 3.1 (2.7 to 15.0) ng/mL at the end of the experiment. In the uncoated setups the corresponding C5a concentrations were 10.1 (6.2 to 17.5) and 19.7 (13.1 to 24.3) ng/mL. Finally, heparin-coated cardiopulmonary bypass circuits were examined in vivo. C5a levels did not increase significantly during the cardiopulmonary bypass period in the heparin-coated group in contrast to the uncoated group, but the postoperative increase in C5a levels was similar in the two groups. We conclude that heparin coating improves biocompatibility by completely abolishing C5a formation in vitro. The discrepancy between the in vitro and the in vivo findings is probably related to the complicated biological turnover of C5a.

This article has been cited by other articles:

				The Society of Thoracic Surgeons Blood Conservatio, V. A. Ferraris, S. P. Ferraris, S. P. Saha, E. A. Hessel II, C. K. Haan, B. D. Royston, C. R. Bridges, R. S.D. Higgins, G. Despotis, et al. Perioperative Blood Transfusion and Blood Conservation in Cardiac Surgery: The Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists Clinical Practice Guideline Ann. Thorac. Surg., May 1, 2007; 83(5_Supplement): S27 - S86. [Abstract] [Full Text] [PDF]

				G. Wimmer-Greinecker, G. Matheis, S. Martens, G. Oremek, U. Abdel-Rahman, and A. Moritz Synthetic protein treated versus heparin coated cardiopulmonary bypass surfaces: similar clinical results and minor biochemical differences Eur. J. Cardiothorac. Surg., August 1, 1999; 16(2): 211 - 217. [Abstract] [Full Text] [PDF]

				M. Ranucci, A. Mazzucco, R. Pessotto, G. Grillone, V. Casati, L. Porreca, R. Maugeri, M. Meli, P. Magagna, S. Cirri, et al. Heparin-coated circuits for high-risk patients: a multicenter, prospective, randomized trial Ann. Thorac. Surg., April 1, 1999; 67(4): 994 - 1000. [Abstract] [Full Text] [PDF]

				V. Videm, T. E. Mollnes, K. Bergh, E. Fosse, B. Mohr, T.-A. Hagve, A. O. Aasen, and J. L. Svennevig HEPARIN-COATED CARDIOPULMONARY BYPASS EQUIPMENT. II. MECHANISMS FOR REDUCED COMPLEMENT ACTIVATION IN VIVO J. Thorac. Cardiovasc. Surg., April 1, 1999; 117(4): 803 - 809. [Abstract] [Full Text] [PDF]

				B. Nilsson, R. Larsson, J. Hong, G. Elgue, K. N. Ekdahl, A. Sahu, and J. D. Lambris Compstatin Inhibits Complement and Cellular Activation in Whole Blood in Two Models of Extracorporeal Circulation Blood, September 1, 1998; 92(5): 1661 - 1667. [Abstract] [Full Text] [PDF]

				C B. Mahoney Heparin-bonded circuits: clinical outcomes and costs Perfusion, May 1, 1998; 13(3): 192 - 204. [Abstract] [PDF]

				Y. J. Gu, P. W. Boonstra, A. A. Rijnsburger, J. Haan, and W. van Oeveren Cardiopulmonary Bypass Circuit Treated With Surface-Modifying Additives: A Clinical Evaluation of Blood Compatibility Ann. Thorac. Surg., May 1, 1998; 65(5): 1342 - 1347. [Abstract] [Full Text] [PDF]

				C. R. Wilhelm, J. Ristich, R. L. Kormos, and W. R. Wagner Monocyte Tissue Factor Expression and Ongoing Complement Generation in Ventricular Assist Device Patients Ann. Thorac. Surg., April 1, 1998; 65(4): 1071 - 1076. [Abstract] [Full Text] [PDF]

				A. Belboul and N. Al-Khaja Does heparin coating improve biocompatibility? A study on complement, blood cells and postoperative morbidity during cardiac surgery Perfusion, December 1, 1997; 12(6): 385 - 391. [Abstract] [PDF]

				G. Hetland, O. Moen, K. Bergh, K. Hogasen, C. E. Hack, T. E. Mollnes, and E. Fosse Both Plasma- and Leukocyte-Associated C5a Are Essential for Assessment of C5a Generation In Vivo Ann. Thorac. Surg., April 1, 1997; 63(4): 1076 - 1080. [Abstract] [Full Text]

				A. H. Kuitunen, L. J. Heikkila, and M. T. Salmenpera Cardiopulmonary Bypass With Heparin-Coated Circuits and Reduced Systemic Anticoagulation Ann. Thorac. Surg., February 1, 1997; 63(2): 438 - 444. [Abstract] [Full Text]

				H E Hogevold, O Moen, E Fosse, P Venge, J Braten, C Andersson, and T Lyberg Effects of heparin coating on the expression of CD11b, CD11c and CD62L by leucocytes in extracorporeal circulation in vitro Perfusion, January 1, 1997; 12(1): 9 - 20. [Abstract] [PDF]

				O. Moen, K. Hogasen, E. Fosse, E. Dregelid, V. Brockmeier, P. Venge, M. Harboe, and T. E. Mollnes Attenuation of Changes in Leukocyte Surface Markers and Complement Activation With Heparin-Coated Cardiopulmonary Bypass Ann. Thorac. Surg., January 1, 1997; 63(1): 105 - 111. [Abstract] [Full Text]

				H. t. Velthuis, P. G. M. Jansen, C. E. Hack, L. Eijsman, and C. R. H. Wildevuur Specific Complement Inhibition With Heparin-Coated Extracorporeal Circuits Ann. Thorac. Surg., April 1, 1996; 61(4): 1153 - 1157. [Abstract] [Full Text]

				H. t. Velthuis, P. G. M. Jansen, H. M. Oudemans-van Straaten, A. Sturk, L. Eijsman, and C. R. H. Wildevuur MYOCARDIAL PERFORMANCE IN ELDERLY PATIENTS AFTER CARDIOPULMONARY BYPASS IS SUPPRESSED BY TUMOR NECROSIS FACTOR J. Thorac. Cardiovasc. Surg., December 1, 1995; 110(6): 1663 - 1669. [Abstract] [Full Text]

				E. Ovrum, E. A. Holen, G. Tangen, F. Brosstad, M. Abdelnoor, M.-A. L. Ringdal, R. Oystese, and R. Istad Completely Heparinized Cardiopulmonary Bypass and Reduced Systemic Heparin: Clinical and Hemostatic Effects Ann. Thorac. Surg., August 1, 1995; 60(2): 365 - 371. [Abstract] [Full Text]

				D. M. Meyer, M. E. Jessen, and R. C. Eberhart Neonatal Extracorporeal Membrane Oxygenation Complicated by Sepsis Ann. Thorac. Surg., April 1, 1995; 59(4): 975 - 980. [Abstract] [Full Text]